华兰疫苗：第三季度归母净利润1.12亿元，同比下降53.94%

Core Viewpoint - Hualan Vaccine reported a significant decline in both revenue and net profit for the third quarter of 2025, indicating challenges in the company's financial performance [1] Financial Performance - In Q3 2025, the company achieved operating revenue of 746 million yuan, a year-on-year decrease of 19.07% [1] - The net profit attributable to shareholders was 112 million yuan, down 53.94% year-on-year [1] - Basic earnings per share for Q3 2025 were 0.1874 yuan [1] Year-to-Date Performance - For the first three quarters of 2025, the company reported total operating revenue of 806 million yuan, reflecting a year-on-year decline of 15.81% [1] - The net profit attributable to shareholders for the first three quarters was 132 million yuan, a decrease of 50.51% compared to the previous year [1] - Basic earnings per share for the first three quarters were 0.2224 yuan [1]